Roche receives FDA approval for the first molecular test to screen for malaria in blood donors - Seite 3

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] CDC.gov “What is malaria? Frequently asked questions. https://www.cdc.gov/malaria/about/index.html
[2] World Health Organisation. (n.d.). World Health Organisation. Retrieved March 21, 2024, from https://www.who.int/health-topics/malaria#tab=tab_1

Roche Global Media Relations
Phone: [phone] / e-mail: [e-mail]

Hans Trees, PhD Phone: [phone]	Nathalie Altermatt Phone: [phone]
Simon Goldsborough Phone: [phone]	Karsten Kleine Phone: [phone]
Nina Mählitz Phone: [phone]	Kirti Pandey Phone: [phone]
Dr. Rebekka Schnell Phone: [phone]	Sileia Urech Phone: [phone]

Roche Investor Relations

Dr. Bruno Eschli Phone: [phone] e-mail: [e-mail]	Dr. Sabine Borngräber Phone: [phone] e-mail: [e-mail]
Dr. Birgit Masjost Phone: [phone] e-mail: [e-mail]

Investor Relations North America

Loren Kalm Phone: [phone] e-mail: [e-mail]

 

Attachment

• 26032024_MR_Cobas Malaria_EN